Matthias Augustin
University of Hamburg
Quality of lifeInternal medicineSurgeryCross-sectional studyDermatologyHealth careIntensive care medicinePhysical therapyDermatology Life Quality IndexPsoriatic arthritisPsoriasis Area and Severity IndexDiseaseMEDLINEQuality of life (healthcare)PsoriasisPopulationGynecologySeverity of illnessFamily medicineMedicine
Publications 719
#1Toni Maria Klein (UHH: University of Hamburg)H-Index: 3
#2Valerie Andrees (UHH: University of Hamburg)H-Index: 3
Last. Christine Blome (UHH: University of Hamburg)H-Index: 25
view all 6 authors...
Living with chronic ulcers can be burdensome and restrictive, with regard to not only physical and psychological but also social well-being. This review aims to analyse social participation in patients with chronic wounds and to compare results across different wound types. A search string was applied in several electronic databases. Results were screened according to predefined inclusion and exclusion criteria. Data of eligible articles were extracted and synthesised narratively. The search rev...
#1C. von Stülpnagel (UHH: University of Hamburg)H-Index: 2
#2Matthias Augustin (UHH: University of Hamburg)H-Index: 61
Last. Rachel Sommer (UHH: University of Hamburg)H-Index: 11
view all 5 authors...
Patients with chronic skin diseases suffer from physical and psychosocial impairments which can lead to a cumulative lifelong burden. Therefore, the concept of cumulative life course impairment (CLCI) was introduced, referring to the nonreversible damage due to the persistent life-long burden. This systematic review (PROSPERO registry number: CRD42020179141) aimed at mapping the risk factors and the associated burden over time in patients with psoriasis, atopic dermatitis (AD) and hidradenitis s...
#1K. Hagenström (UHH: University of Hamburg)H-Index: 3
#2Kerstin Protz (UHH: University of Hamburg)H-Index: 12
Last. Matthias Augustin (UHH: University of Hamburg)H-Index: 61
view all 4 authors...
Patients with chronic leg ulcer, pressure ulcer, or diabetic foot ulcer suffer from significant disease burden. With a view to improving healthcare provision sustainably, a predictive model of time to closure (time-to-event analysis) based on claims data was developed. To identify potential predictors of wound closure, clinical information absent from statutory health insurance (SHI) data was modelled. In patients with leg ulcers, age of the patient (hazard ratios [HR] 0.99), increasing number o...
#1Petra Staubach (University of Mainz)H-Index: 38
#2Caroline Mann (University of Mainz)H-Index: 4
Last. Jana Petersen (UHH: University of Hamburg)H-Index: 3
view all 8 authors...
BACKGROUND To date, robust epidemiological metrics as well as data on comorbidity in pediatric urticaria are lacking. They form the basis for the design of efficient healthcare. METHODS Retrospective study to analyze epidemiological data in pediatric urticaria. The analysis is based on routine data of a health insurance company operating throughout Germany (DAK-Gesundheit). Insured people under 18 years of age who received at least one confirmed outpatient or inpatient urticaria diagnosis accord...
Last. Stefanie MacheH-Index: 9
view all 7 authors...
In der Pflegebranche nehmen Arbeitsunfahigkeitstage durch verschiedene Fehlbelastungen zu, welches die Relevanz der Betrieblichen Gesundheitsforderung (BGF) hervorhebt. Der Artikel soll die Thematik der BGF in der Pflege beleuchten und zudem eine Ubersicht von bestehenden betrieblichen Gesundheitsforderungsmasnahmen im Setting Pflege bieten. In einer explorativen Literaturrecherche werden bisher verfugbare Erkenntnisse aus der BGF in der Pflege recherchiert und zusammengefasst. Aus diesen Forsch...
#1Ulrich MrowietzH-Index: 76
#2Peter C.M. van de Kerkhof (Radboud University Nijmegen)H-Index: 53
view all 17 authors...
SummaryThe 29th EADV Virtual Congress took place between the 29th-31st of October 2020. On October 29th, there was a Session on systemic treatment in which Professors Ulrich Mrowietz and Mar Llamas-Velasco presented the latest research on the efficacy of dimethyl fumarate (DMF) treatment for moderate-to-severe plaque psoriasis (BRIDGE and DIMESKIN 1 studies, respectively). The accepted DMF abstract from Professor Matthias Augustin and others, on the SKILL study, is also presented here. Data from...
#1Julia-Tatjana Maul (UZH: University of Zurich)H-Index: 8
#1J.-T. Maul (UZH: University of Zurich)
Last. Alexander A. Navarini (UZH: University of Zurich)H-Index: 34
view all 14 authors...
BACKGROUND Psoriasis is a stigmatizing disease that often affects female patients more negatively than male patients. Very little systematic data on the treatment responses related to gender exists. OBJECTIVES This two-country, multi-centre, prospective, non-interventional registry study aimed to evaluate potential gender differences with respect to systemic anti-psoriatic treatment. METHODS Data of patients with moderate to severe psoriasis participating in the German (PsoBest) or Swiss (SDNTT)...
1 CitationsSource
#1N Kirsten (UHH: University of Hamburg)H-Index: 4
#2Franziska Gensel (UHH: University of Hamburg)
Last. Matthias Augustin (UHH: University of Hamburg)H-Index: 61
view all 3 authors...
#1Andreas Wollenberg (LMU: Ludwig Maximilian University of Munich)H-Index: 65
#2T. Nakahara (Kyushu University)H-Index: 5
Last. Carle Paul (University of Toulouse)H-Index: 82
view all 15 authors...
BACKGROUND Baricitinib is an oral, selective, reversible Janus kinase 1/2 inhibitor approved in the European Union and Japan and under investigation in the United States for treatment of atopic dermatitis (AD). OBJECTIVES To evaluate the impact of baricitinib plus background topical corticosteroids (TCS) on health-related quality of life (HRQoL), how AD symptoms impact work productivity and life functioning, and treatment benefit using patient-reported outcome (PRO) assessments in patients with ...
#1Melinda GooderhamH-Index: 32
#2Boni E. ElewskiH-Index: 64
Last. Peter FoleyH-Index: 32
view all 11 authors...
OBJECTIVE: We describe patient-reported outcomes and quality of life through 5 years of treatment in patients with moderate-to-severe plaque psoriasis in the UNCOVER-1 and -2 studies. METHODS: This analysis included patients who were randomized to ixekizumab every 2 weeks then received ixekizumab every 4 weeks during the maintenance period, and who achieved static physician global assessment (0,1) at week 12, completed week 60, and entered the long-term extension period (weeks 60–264). Outcomes ...